Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

Effective SARS-CoV-2 vaccines are urgently needed. Although most vaccine strategies have
focused on systemic immunization, here we compared the protective efficacy of 2 …

Vaccines are instrumental and indispensable in the fight against the COVID-19 pandemic.
Several recent SARS-CoV-2 variants are more transmissible and evade infection-or vaccine …

Background In late 2021, the SARS-CoV-2 Omicron (B. 1.1. 529) variant of concern (VoC)
was reported with many mutations in the viral spike protein that were predicted to enhance …

The new vaccines against SARS-CoV-2 are novel in terms of specificity, their wide
dissemination across the global population and the inclusion of newly licensed mRNA …

The COVID-19 pandemic triggered the intensity of the pursuit of vaccines that had not been
seen before and were developed at an unprecedented speed, approved, and delivered for …

The US Food and Drug Administration only gave emergency use authorization of the
BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June …

Several variants of SARS-CoV-2 have emerged. Those with mutations in the angiotensin-
converting enzyme (ACE2) receptor binding domain (RBD) are associated with increased …

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence of new variant lineages that have exacerbated the COVID-19 …

Vaccines utilizing modified messenger RNA (mRNA) technology have shown robust
protective efficacy against SARS-CoV-2 in humans. As the virus continues to evolve in both …